Alkermes PLC (ALKS) Scheduled to Post Quarterly Earnings on Wednesday
Alkermes PLC (NASDAQ:ALKS) is set to announce its earnings results before the market opens on Wednesday, July 26th. Analysts expect the company to announce earnings of ($0.01) per share for the quarter.
Alkermes PLC (NASDAQ:ALKS) last issued its earnings results on Thursday, April 27th. The company reported ($0.31) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.24) by $0.07. Alkermes PLC had a negative net margin of 25.61% and a negative return on equity of 9.76%. The business had revenue of $191.80 million during the quarter, compared to analysts’ expectations of $195.79 million. During the same period in the prior year, the business posted ($0.16) EPS. The business’s revenue was up 22.3% on a year-over-year basis. On average, analysts expect Alkermes PLC to post $-0.04 EPS for the current fiscal year and $0.47 EPS for the next fiscal year.
Alkermes PLC (ALKS) opened at 58.01 on Wednesday. The stock’s market cap is $8.89 billion. Alkermes PLC has a 52 week low of $41.93 and a 52 week high of $63.40. The stock has a 50 day moving average of $58.62 and a 200-day moving average of $57.52.
In other news, Director Paul J. Mitchell sold 1,500 shares of the business’s stock in a transaction on Thursday, June 1st. The shares were sold at an average price of $57.49, for a total value of $86,235.00. Following the completion of the sale, the director now directly owns 9,500 shares in the company, valued at $546,155. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Richard F. Pops sold 50,000 shares of the business’s stock in a transaction on Wednesday, May 17th. The stock was sold at an average price of $58.19, for a total transaction of $2,909,500.00. Following the completion of the sale, the director now owns 680,406 shares of the company’s stock, valued at $39,592,825.14. The disclosure for this sale can be found here. Insiders sold 139,500 shares of company stock valued at $8,086,675 over the last 90 days. 5.34% of the stock is owned by corporate insiders.
Several analysts have commented on ALKS shares. J P Morgan Chase & Co set a $78.00 target price on shares of Alkermes PLC and gave the stock a “buy” rating in a research report on Thursday, April 27th. Cowen and Company reissued a “positive” rating and issued a $65.00 target price on shares of Alkermes PLC in a research report on Tuesday, March 21st. Jefferies Group LLC reissued a “buy” rating and issued a $70.00 target price on shares of Alkermes PLC in a research report on Monday, April 3rd. Credit Suisse Group reissued a “buy” rating and issued a $70.00 target price on shares of Alkermes PLC in a research report on Wednesday, June 7th. Finally, Leerink Swann downgraded shares of Alkermes PLC from an “outperform” rating to a “market perform” rating and decreased their target price for the stock from $68.00 to $61.00 in a research report on Tuesday, June 13th. Seven investment analysts have rated the stock with a hold rating and five have given a buy rating to the stock. The stock has an average rating of “Hold” and an average target price of $62.55.
TRADEMARK VIOLATION WARNING: This piece was originally posted by American Banking News and is owned by of American Banking News. If you are accessing this piece on another domain, it was copied illegally and reposted in violation of United States & international copyright laws. The correct version of this piece can be read at https://www.americanbankingnews.com/2017/07/19/alkermes-plc-alks-scheduled-to-post-quarterly-earnings-on-wednesday.html.
About Alkermes PLC
Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS).
Receive News & Ratings for Alkermes PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes PLC and related companies with MarketBeat.com's FREE daily email newsletter.